Not Yet Recruiting
A First-in-human Study of KT502 Administered Subcutaneously to Adult Participants With Rheumatoid Arthritis (RA)
NCT07564154
- Conditions
- Arthritis, Arthritis, Rheumatoid, Autoimmune Diseases, +7 more
- Locations
-
- Kali Therapeutics Trial Site Bayswater, Victoria, Australia
- Kali Therapeutics Trial Site Auckland, NZ, New Zealand